Difluoromescaline

Difluoromescaline
Clinical data
Other names	DFM; 4-Difluoromethoxy-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-difluoromethoxyphenethylamine
Routes of; administration	Oral
Drug class	Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Pharmacokinetic data
Duration of action	12–18 hours
Identifiers
	IUPAC name 2-[4-(difluoromethoxy)-3,5-dimethoxyphenyl]ethanamine;
CAS Number	1178367-63-9;
PubChem CID	54930734;
ChemSpider	33250437;
Chemical and physical data
Formula	C11H15F2NO3
Molar mass	247.242 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC(=CC(=C1OC(F)F)OC)CCN;
	InChI InChI=1S/C11H15F2NO3/c1-15-8-5-7(3-4-14)6-9(16-2)10(8)17-11(12)13/h5-6,11H,3-4,14H2,1-2H3; Key:MMARNDCKXDBJES-UHFFFAOYSA-N;

Difluoromescaline (DFM), also known as 4-difluoromethoxy-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline. It is a difluorinated derivative of mescaline. The drug's dose range is 50 to 100 mg orally and its duration is 12 to 18 hours. It is about 3- or 4-fold more potent than mescaline and has a longer duration in comparison. The drug is said to produce strong psychedelic effects. Difluoromescaline interacts with serotonin receptors and acts as a low-potency full agonist of the serotonin 5-HT_2A receptor. It was first described in the scientific literature by Daniel Trachsel in 2012. The drug's pharmacology was studied in more detail in 2021. It is not a controlled substance in Canada as of 2025.